Orion Genomics brings cutting edge scientific expertise, innovation, proprietary technologies and commercial and academic partnerships throughout the globe to change how the world approaches feeding, fueling and healing itself. With over 100 patents and patents pending, a research and clinical division, strong leadership, and advisory boards, Orion Genomics is uniquely positioned to provide strategic and technological support to partners in agriculture and human health.
The Genomics Research and Service Division has active biomarker discovery programs, the latest sequencing technologies and expertise in all areas of genomics research to support our strategic alliances and our internal product development pipeline.
The Clinical Research and Service Division is centered around our “CLIA-Certified” clinical laboratory. This laboratory allows us to seamlessly move assays from our research lab to a clinical lab where they can be further developed and tested in a regulated environment.
Orion Biosains is a fully-owned subsidiary of Orion Genomics, with headquarters in Kuala Lumpur, Malaysia. Orion Biosains is innovating agriculture through bioscience by supporting the oil palm industry in Southeast Asia with plans to expand globally. They are commercializing the joint discoveries of the Malaysian Palm Oil Board and Orion Genomics, offering technical expertise, flexible business solutions and strategic partnerships to oil palm seed producers and growers.
Orion Genomics launches clinical diagnostics lab, granted CAP accreditation
For Immediate Release
February 7, 2014
Canale Communications for Orion Genomics
St. Louis, Missouri − February 7, 2014 − Orion Genomics, a leading developer of epigenetic − based diagnostics, announced today the receipt of certification by the College of American Pathologists, for meeting standards of excellence in the practice of laboratory medicine. On April 9, 2013, Orion Genomics also received licensure and certificate of registration from the State of Missouri as a CLIA laboratory, and launched the Orion Genomics Clinical Labs. The Centers for Medicare & Medicaid Services (CMS) ensures high − quality standards of diagnostic testing on humans through regulatory oversight through the Clinical Laboratory Improvement Amendments of 1998 (CLIA).
”CAP accreditation and CLIA certification are critical steps in the validation of our proprietary colon cancer risk test in large prospective cohorts, which can now begin under the highest performance standards in the Orion Genomics Clinical Laboratory”, said Nathan Lakey, President and Chief Executive Officer of Orion. ”These achievements also enables us to market assay design and validation services to companies with novel diagnostics in development.” The DNA molecule not only contains information based on its sequence of As, Ts, Gs and Cs but also has a second layer of information (or epigenetic layer) written on top of the DNA sequence. The second layer is based on the addition of methyl groups to the DNA molecule’s backbone, which creates a binary language that controls whether or not a gene is turned on or off, also called gene silencing. Orion’s colon cancer risk test measures the loss of imprinting (LOI) of the insulin−like Growth Factor II gene , a sporadic epigenetic defect which occurs in ~10% of the population and leads to an increased expression of a potent growth factor, a marker which may be predictive of future cancer risk. Orion exclusively licensed a portfolio of patents from the Johns Hopkin’s University covering LOI testing, and is collaborating with leading Hopkins researchers to design high performing molecular assays for LOI testing